Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Protagenic Therapeutics, Inc.\new files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2026
FY2026
Revenue
0
0
0
0
0
0
0
Research and development
0.72
0.88
0.81
0.7
1.14
1.59
3.06
3.84
0.38
0.9
General and administrative
1.65
1.43
1.28
1.85
3
1.97
1.21
1.76
0.08
0.33
Operating expenses
2.37
2.31
2.09
2.55
4.14
3.56
4.53
5.7
2.59
4.5
Operating income
-2.37
-2.31
-2.09
-2.55
-4.14
-3.56
-4.53
-5.7
-2.59
-4.5
Interest expense
0.25
0.5
0.14
0.11
Interest income
0
0.03
0.19
0.26
0.04
Other non-operating income
0.11
-0.24
0.34
0
-0.38
0
-0.47
0.18
-1
5.87
Pre-tax income
-2.26
-2.56
-1.75
-2.55
-4.52
-3.56
-5
-5.53
-3.59
1.37
Net income
-2.26
-2.56
-1.75
-2.55
-4.52
-3.56
-5
-5.53
-3.59
1.37
EBITDA
-2.37
-2.31
-2.09
-2.55
-3.56
-4.5
-5.65
-4.45
EPS, basic
-0.22
-0.25
-0.17
-0.25
-1.24
-0.82
-1.15
-1.13
-0.67
0.59
EPS, diluted
-0.22
-0.25
-0.17
-0.25
-0.31
-0.82
-1.15
-1.13
-0.67
0.59
Shares, basic (weighted)
10.3
10.3
10.3
10.3
3.69
4.32
4.34
4.9
5.37
2.33
Shares, diluted (weighted)
10.3
10.3
10.3
10.3
14.7
4.32
4.34
4.9
5.37
2.33
Balance sheet
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2026
FY2026
Cash and equivalents
0.4
0.36
0.8
0.67
0.54
0.22
1.29
0.08
0.01
1.51
Short-term investments
9.83
7.76
2.77
Inventory
0
Other current assets
0.09
0.08
0.04
0.21
0.69
0.06
0.14
0.04
0.06
0.03
Total current assets
1.78
0.7
0.84
0.88
11.1
8.04
4.2
1.88
0.09
1.54
Property, plant and equipment
0
0
0
0
0.12
0.07
0.06
0.01
Intangible assets
2.09
Total assets
1.78
0.7
0.84
0.88
11.1
8.04
4.32
1.96
0.09
3.65
Accounts payable
0.14
0.23
0.87
0.57
0.5
0.67
0.96
0.95
Accrued liabilities
0.25
0.08
Total current liabilities
0.56
0.91
1.2
0.66
0.8
1.12
0.66
0.94
5.04
1.03
Total liabilities
0.56
0.91
1.48
2.03
1.12
1.12
0.66
0.94
5.04
1.03
Paid-in capital
12.2
13.4
14.7
16.7
32.4
33.4
34.6
37.4
0.46
6.99
Retained earnings
-10.8
-13.4
-15.2
-17.7
-22.2
-25.8
-30.8
-36.3
-5.4
-4.03
Other comprehensive income
-0.17
-0.17
-0.17
-0.17
-0.25
-0.68
-0.11
-0.13
-0.13
Shareholders' equity
1.22
-0.21
-0.63
-1.15
9.94
6.92
3.67
-3.32
-4.95
2.62
Total equity
1.22
-0.21
-0.63
-1.15
9.94
6.92
3.67
-3.32
-4.95
2.62
Total liabilities and equity
1.78
0.7
0.84
0.88
11.1
8.04
4.32
1.96
0.09
3.65
Shares outstanding
10.3
10.3
10.3
10.4
4.3
4.32
4.44
0.52
5.8
1.81
Cash flow statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2026
FY2026
Net income
-2.26
-2.56
-1.75
-2.55
-4.52
-3.56
-5
-5.53
-3.59
1.37
Depreciation and amortization
0
0
0
0
0
0.03
0.05
0.05
Stock-based compensation
0.89
1.13
0.8
1.65
1.52
0.86
0.67
0.92
0.42
Change in inventory
-0
-0
Change in payables
0.02
0.1
0.66
-0.2
0.34
-0.09
-0.18
0.46
0.18
1.04
Cash from operations
-1.38
-1.07
-0.49
-1.35
-2.8
-1.99
-3.7
-4.22
-1.77
-2.81
Capital expenditures
-0
-0.15
-0
Purchases of investments
-10.4
-0.03
-2.76
-0.3
Sales and maturities of investments
0.49
1.63
7.69
3.1
Cash from investing
-1.29
1.05
0.25
-9.91
1.6
4.78
2.8
0.63
Stock issued
0
0.4
Cash from financing
0.67
1.22
12.6
1.96
1.81
3.87
Exchange rate effect
-0.03
-0.01
Net change in cash
-2.7
-0.04
0.44
-0.13
-0.13
-0.33
1.07
0.55
0.04
1.7
Free cash flow
-2
-3.85
-2.81
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.78 on September 28, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
316.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
195.3%
Net income / average total assets.
Return on invested capital (ROIC)
-290.5%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
3,997.0%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
-56.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.66x
Current assets / current liabilities.
Quick ratio
0.53x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.53x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$1.10
Cash from operations / diluted weighted shares.
Book value per share
$0.95
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
0.26x
Market cap / net income. Only when net income is positive.
P/B
0.82x
Market cap / shareholders' equity. Only when equity is positive.
Earnings yield
386.8%
Net income / market cap (the inverse of P/E).
What was Protagenic Therapeutics, Inc.\new's revenue in fiscal 2026?
Protagenic Therapeutics, Inc.\new reported revenue of $0.0 for fiscal 2026.
Was Protagenic Therapeutics, Inc.\new profitable in fiscal 2026?
Yes. Net income was $1.4M, a net margin of -.
How much free cash flow did Protagenic Therapeutics, Inc.\new generate in fiscal 2026?
Cash from operations of $2.8M minus capital expenditures of $3.3K left free cash flow of -$2.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.